In vitro transcribed (IVT) mRNA drugs: technical progress and application prospect
10.16438/j.0513-4870.2023-0201
- VernacularTitle:体外转录mRNA药物的技术进展和应用前景
- Author:
Shu-ting HOU
;
Chuan-fei YU
;
Lan WANG
;
Jun-zhi WANG
- Publication Type:Research Article
- Keywords:
italic>in vitro transcribed mRNA technology;
mRNA sequence design;
mRNA delivery;
mRNA drug;
quality control
- From:
Acta Pharmaceutica Sinica
2023;58(8):2047-2058
- CountryChina
- Language:Chinese
-
Abstract:
The in vitro transcribed (IVT) mRNA technology has progressed rapidly and the application of mRNA vaccines in the COVID-19 pandemic made it become the most talked-about topic. Compared with protein drugs, IVT mRNA has a lower cost; it can be modular produced and its sequence can be modified easily, so it has a broad application prospect. However, due to its short history, mRNA drugs face the problem of lacking sufficient clinical data, and there is no quality control standard for mRNA drugs except mRNA vaccines. We overview the sequence design, delivery vectors, administration, application prospect and safety considerations of mRNA drugs. We also discussed the quality control of mRNA drugs briefly.
